论文部分内容阅读
Objective:To reveal the mechanism and effect of SU5416 in the treatment of mouse Lewis cancer in vivo.Methods:Lewis cell was transplanted into groin of C57/B6 mouse by subcutaneous injection,then SU5416 was administrated intraperitoneally to investigate the impact of SU5416 on tumor angiogenesis and growth in vivo.32 mice were treated with SU5416 at two different doses every day until the end-point.As a control,8 mice received no treatment and 8 mice were treated with vehicle (DMSO) only after implantation.Results:Median survival in the treated group was statistically longer compared to that in the control groups (P＜0.05) and no significant systemic adverse was observed.Histological analysis of the treated tumors showed an increase in necroses and reduced in angiogenesis compared to the control tumors.Furthermore,the percent of apoptotic cells increased in the treated tumors by FCM,the expressions of VEGF and KDR had no change after SU5416 administration by weste blot,Conclusion:SU5416 may be useful therapeutics drug that specifically inhibits the enzymatic activity of KDR kinase and could down regulate the tumor angiogenesis.